These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31206600)

  • 1. Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis.
    Ahmed S; Chakka S; Concha J; Krain R; Feng R; Werth VP
    Br J Dermatol; 2020 Apr; 182(4):949-954. PubMed ID: 31206600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change.
    Anyanwu CO; Fiorentino DF; Chung L; Dzuong C; Wang Y; Okawa J; Carr K; Propert KJ; Werth VP
    Br J Dermatol; 2015 Oct; 173(4):969-74. PubMed ID: 25994337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: A comprehensive review.
    Ahmed S; Chen KL; Werth VP
    Semin Arthritis Rheum; 2020 Jun; 50(3):458-462. PubMed ID: 32057402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument.
    Yassaee M; Fiorentino D; Okawa J; Taylor L; Coley C; Troxel AB; Werth VP
    Br J Dermatol; 2010 Mar; 162(3):669-73. PubMed ID: 19863510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life.
    Robinson ES; Feng R; Okawa J; Werth VP
    Br J Dermatol; 2015 Jan; 172(1):169-74. PubMed ID: 24909747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis.
    Klein RQ; Bangert CA; Costner M; Connolly MK; Tanikawa A; Okawa J; Rose M; Fakharzadeh SS; Fiorentino D; Lee LA; Sontheimer RD; Taylor L; Troxel AB; Werth VP
    Br J Dermatol; 2008 Sep; 159(4):887-94. PubMed ID: 18616782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life in dermatomyositis.
    Goreshi R; Chock M; Foering K; Feng R; Okawa J; Rose M; Fiorentino D; Werth V
    J Am Acad Dermatol; 2011 Dec; 65(6):1107-16. PubMed ID: 21722989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool-Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists.
    Tiao J; Feng R; Berger EM; Brandsema JF; Coughlin CC; Khan N; Kichula EA; Lerman MA; Lvovich S; McMahon PJ; Rider LG; Rubin AI; Scalzi LV; Smith DM; Taxter AJ; Treat JR; Williams RP; Yum SW; Okawa J; Werth VP
    Br J Dermatol; 2017 Oct; 177(4):1086-1092. PubMed ID: 28421601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the Correlation Between Disease Severity Indices and Quality of Life Measurement Tools in Pemphigus.
    Krain RL; Kushner CJ; Tarazi M; Gaffney RG; Yeguez AC; Zamalin DE; Pearson DR; Feng R; Payne AS; Werth VP
    Front Immunol; 2019; 10():2571. PubMed ID: 31781098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists.
    Tiao J; Feng R; Bird S; Choi JK; Dunham J; George M; Gonzalez-Rivera TC; Kaufman JL; Khan N; Luo JJ; Micheletti R; Payne AS; Price R; Quinn C; Rubin AI; Sreih AG; Thomas P; Okawa J; Werth VP
    Br J Dermatol; 2017 Feb; 176(2):423-430. PubMed ID: 28004387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating change in disease activity needed to reflect meaningful improvement in quality of life for clinical trials in cutaneous lupus erythematosus.
    Chakka S; Krain RL; Ahmed S; Concha JSS; Feng R; Merrill JT; Werth VP
    J Am Acad Dermatol; 2021 Jun; 84(6):1562-1567. PubMed ID: 32682879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI).
    Rider LG; Werth VP; Huber AM; Alexanderson H; Rao AP; Ruperto N; Herbelin L; Barohn R; Isenberg D; Miller FW
    Arthritis Care Res (Hoboken); 2011 Nov; 63 Suppl 11(0 11):S118-57. PubMed ID: 22588740
    [No Abstract]   [Full Text] [Related]  

  • 13. Apremilast in Recalcitrant Cutaneous Dermatomyositis: A Nonrandomized Controlled Trial.
    Bitar C; Ninh T; Brag K; Foutouhi S; Radosta S; Meyers J; Baddoo M; Liu D; Stumpf B; Harms PW; Saba NS; Boh E
    JAMA Dermatol; 2022 Dec; 158(12):1357-1366. PubMed ID: 36197661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon β in dermatomyositis.
    Huard C; Gullà SV; Bennett DV; Coyle AJ; Vleugels RA; Greenberg SA
    Br J Dermatol; 2017 May; 176(5):1224-1230. PubMed ID: 27564228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis.
    Wolstencroft PW; Chung L; Li S; Casciola-Rosen L; Fiorentino DF
    JAMA Dermatol; 2018 Jan; 154(1):44-51. PubMed ID: 29114741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on Epidemiology and Clinical Assessment Tools of Cutaneous Lupus Erythematosus and Dermatomyositis.
    Chang YC; Werth VP
    Curr Dermatol Rep; 2013 Mar; 2(1):48-57. PubMed ID: 33585073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life.
    Hundley JL; Carroll CL; Lang W; Snively B; Yosipovitch G; Feldman SR; Jorizzo JL
    J Am Acad Dermatol; 2006 Feb; 54(2):217-20. PubMed ID: 16443050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary definition of cutaneous flare in dermatomyositis: A retrospective review.
    Dan J; Afarideh M; Sprow G; Keyes E; Diaz D; Vazquez T; Kodali N; Werth VP
    J Am Acad Dermatol; 2023 Jan; 88(1):190-191. PubMed ID: 35381299
    [No Abstract]   [Full Text] [Related]  

  • 19. Responsiveness of quality-of-life measures in patients with peripheral vascular malformations: the OVAMA project.
    Lokhorst MM; Horbach SER; Waner M; O TM; van der Vleuten CJM; Mokkink LB; van der Horst CMAM; Spuls PI
    Br J Dermatol; 2020 Jun; 182(6):1395-1403. PubMed ID: 31628861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM.
    Goreshi R; Okawa J; Rose M; Feng R; Lee LA; Hansen CB; Bangert CA; Connolly MK; Davis MD; Callen JP; Fett NM; Fakharzadeh SS; Clarke JT; Werth VP
    J Invest Dermatol; 2012 Apr; 132(4):1117-24. PubMed ID: 22217740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.